logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
delete
arrow
返回
K

Ken Kato

national cancer center hospital

75H指数
837论文数
3.0W被引数
收录论文 200
发表时间
logo
First-line tislelizumab plus chemotherapy versus placebo plus chemotherapy in unresectable advanced/metastatic esophageal squamous cell carcinoma: minimum 3-year survival follow-up of a randomized phase 3 trial (RATIONALE-306)一线替雷利珠单抗联合化疗对比安慰剂联合化疗在不可切除的局部晚期/转移性食管鳞状细胞癌中的应用：一项随机III期试验（RATIONALE-306）3年生存随访的最低数据
errNature Communications
IF15.7
err2026-09-03
err0
errOAAI
errHarry H. Yoon; Ken Kato; Eric Raymond; Richard Hubner; Yongqian Shu; Yueyin Pan; Sook Ryun Park; Takashi Kojima; Chen-Yuan Lin; Lucjan Wyrwicz; David Tougeron; Ryu Ishihara; Kaijun Wang; Yanyan Peng; Jianming Xu
err分享
err收藏
Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648纳武利尤单抗联合化疗或伊匹木单抗对比化疗作为晚期食管鳞状细胞癌一线治疗的5年随访结果：CheckMate 648研究
errAnnals of Oncology
IF65.4
err2026-08-10
err0
errOAAI
errK. Kato; J. Ajani; Y. Doki; J. Xu; L. Wyrwicz; S. Motoyama; T. Ogata; H. Kawakami; C-H. Hsu; A. Adenis; F. el Hajbi; M. Di Bartolomeo; M. Ignez Braghiroli; E. Holtved; T. Makino; M. Blum Murphy; J. Zhang; P. Sharma; B. He; M. Lei
err分享
err收藏
First-line pembrolizumab plus chemotherapy versus chemotherapy alone for advanced esophageal cancer: 5-year extended follow-up in the Japanese subgroup of KEYNOTE-590一线帕博利珠单抗联合化疗与化疗单药治疗晚期食管癌：KEYNOTE-590试验的日本亚组5年扩展随访
errEsophagus
IF3.8
err2026-07-01
err0
errOAAI
errKato, Ken; Kojima, Takashi; Hara, Hiroki; Tsuji, Akihito; Yasui, Hisateru; Muro, Kei; Satoh, Taroh; Yatsuzuka, Naoyoshi; Sakata, Tomoko; Han, Shirong; Doi, Toshihiko
err分享
err收藏
An Integrated Individual Patient-Level Database from JCOG Trials in Esophageal Cancer: A Research Platform (JCOG2512A)食管癌JCOG临床试验的集成个体患者级数据库：一个研究平台（JCOG2512A）
errEuropean Journal of Surgical Oncology
IF2.9
err2026-06-15
err0
PREAI
errKota Kawabata; Satoru Matsuda; Takahiro Tsushima; Koshiro Ishiyama; Yuya Ishikawa; Ryunosuke Machida; Takeshi Uozumi; Keita Sasaki; Haruhiko Fukuda; Ken Kato; Hiroyuki Daiko; Hiroya Takeuchi
err分享
err收藏
Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study帕博利珠单抗联合化疗与化疗对比治疗晚期食管癌：KEYNOTE-590随机III期研究的5年扩展随访
errESMO Open
IF8.3
err2025-11-18
err0
errOAAI
errJ.-P. Metges; K. Kato; J.-M. Sun; L. Shen; P.C. Enzinger; A. Adenis; T. Doi; T. Kojima; Z. Li; S.-B. Kim; B.C. Cho; W. Mansoor; S.-H. Li; P. Sunpaweravong; M. Alsina; G.L. Buchschacher; H. Hara; A. Tsuji; J. Wu; S. Shah
err分享
err收藏
Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up替雷利珠单抗 + 化疗在胃癌中的应用：长期RATIONALE-305随机试验随访
errAdvances in Therapy
IF4
err2025-11-18
err0
errOAAI
errMarcia Cruz-Correa; Do-Youn Oh; Ken Kato; Josep Tabernero; Yuxian Bai; Jianhua Shi; Keun-Wook Lee; Hidekazu Hirano; David Spigel; Lucjan Wyrwicz; Roberto Pazo Cid; Antonio Cubillo Gracián; Yaling Xu; Tao Sheng; Silu Yang; Rui-Hua Xu; Markus Moehler
err分享
err收藏
Real-world comparison between neoadjuvant FLOT therapy and DCF therapy for resectable esophagogastric junction adenocarcinoma可切除食管胃结合部腺癌的新辅助FLOT疗法与DCF疗法真实世界比较
errEsophagus
IF3.8
err2025-11-01
err0
errOAAI
errShiraishi, Kazuhiro; Yamamoto, Shun; Hirose, Toshiharu; Imazeki, Hiroshi; Yokoyama, Kazuki; Honma, Yoshitaka; Hashimoto, Taiki; Kashihara, Tairo; Kurita, Daisuke; Ishiyama, Koshiro; Oguma, Junya; Igaki, Hiroshi; Daiko, Hiroyuki; Seto, Yasuyuki; Kato, Ken
err分享
err收藏
Thoracoscopic versus open oesophagectomy for patients with oesophageal cancer (JCOG1409 MONET): a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial胸腔镜与开胸食管切除术治疗食管癌患者（JCOG1409 MONET）：一项多中心、开放标签、随机对照、III期、非劣效性试验
errThe Lancet Gastroenterology & Hepatology
IF38.6
err2025-10-13
err0
PREAI
errHiroya Takeuchi; Ryunosuke Machida; Masahiko Ando; Yasuhiro Tsubosa; Hirotoshi Kikuchi; Hirofumi Kawakubo; Kazuhiro Noma; Masaki Ueno; Takahiro Tsushima; Takeo Bamba; Takeo Fujita; Yoichi Hamai; Tomokazu Kakishita; Hiroyuki Daiko; Kazuo Koyanagi; Satoru Matsuda; Ken Kato; Keita Sasaki; Ryosuke Kita; Yuko Kitagawa
err分享
err收藏
The safety and short-term efficacy of nivolumab plus ipilimumab for advanced esophageal squamous cell carcinoma
errEsophagus
IF3.8
err2025-10-01
err0
errOAAI
errShiraishi, Kazuhiro; Yamamoto, Shun; Yoshinami, Yuri; Ogura, Nozomu; Itoyama, Mai; Imazeki, Hiroshi; Yokoyama, Kazuki; Honma, Yoshitaka; Kashihara, Tairo; Kurita, Daisuke; Ishiyama, Koshiro; Oguma, Junya; Igaki, Hiroshi; Daiko, Hiroyuki; Seto, Yasuyuki; Kato, Ken
err分享
err收藏
Safety and short-term efficacy of neoadjuvant FLOT therapy in cisplatin-unfit patients with resectable esophageal squamous cell carcinoma纳武单抗在可切除食管鳞状细胞癌顺铂不耐受患者中的安全性及短期疗效
errEsophagus
IF3.8
err2025-10-01
err0
errOAAI
errYoshinami, Yuri; Yamamoto, Shun; Shiraishi, Kazuhiro; Imazeki, Hiroshi; Yokoyama, Kazuki; Honma, Yoshitaka; Kurita, Daisuke; Ishiyama, Koshiro; Oguma, Junya; Hashimoto, Taiki; Kashihara, Tairo; Daiko, Hiroyuki; Kato, Ken
err分享
err收藏
Quality indicator survey of clinical practice guidelines for esophagogastric junction cancer 2023贲门癌临床实践指南质量指标调查 2023
errDISEASES OF THE ESOPHAGUS
IF2.3
err2025-10-01
err0
errOAAI
errMatsuda, Satoru; Wijnhoven, Bas; Lordick, Florian; Bhandari, Pradeep; Liu, Fenglin; Kato, Ken; Gotoda, Takuji; Ferri, Lorenzo; Takeuchi, Hiroya; Kakeji, Yoshihiro; Yang, Han-Kwang; Kitagawa, Yuko
err分享
err收藏
Association Between Immune-Related Adverse Events and Treatment Outcomes in Advanced Gastric Cancer Patients Receiving Nivolumab Plus Chemotherapy: A Retrospective StudyYamamoto, K.; Hirano, H.; Hirose, T.; Shoji, H.; Okita, N.; Takashima, A.; Kato, K. 免疫相关不良事件与接受纳武利尤单抗联合化疗的晚期胃癌患者治疗效果之间的关联：一项回顾性研究。Cancer Med. 2025, 14, e71252. [Google Scholar] [CrossRef]
errCANCER MEDICINE
IF3.1
err2025-09-17
err0
errOAAI
errYamamoto, Kazumasa; Hirano, Hidekazu; Hirose, Toshiharu; Shoji, Hirokazu; Okita, Natsuko; Takashima, Atsuo; Kato, Ken
err分享
err收藏
Precemtabart tocentecan, an anti-CEACAM5 antibody–drug conjugate, in metastatic colorectal cancer: a phase 1 trial普雷西坦单抗（抗CEACAM5抗体偶联药物），在转移性结直肠癌中的1期临床试验
errNature Medicine
IF50
err2025-07-30
err0
errOAAI
errScott Kopetz; Valentina Boni; Ken Kato; Kanwal P. S. Raghav; Maria Vieito; Athanasios Pallis; Christina Habermehl; Abdul Siddiqui; Perrine Courlet; Willem Sloot; Sabine Raab-Westphal; Felix Hart; Ildefonso Rodriguez-Rivera
err分享
err收藏
Classification of Japanese type 1 diabetes based on clinical phenotypes and its association with diabetic complications: Across-sectional study基于临床表型的日本1型糖尿病分类及其与糖尿病并发症的关联：一项横断面研究
errJournal of Diabetes Investigation
IF3
err2025-07-02
err0
errOAAI
errTakafumi Masuda; Naoto Katakami; Naohiro Taya; Kazuyuki Miyashita; Mitsuyoshi Takahara; Ken Kato; Iichiro Shimomura
err分享
err收藏
Postoperative Recurrence Pattern of Clinical Stage I Esophageal Cancer After Esophagectomy with Two- or Three-Field Lymph Node Dissection: Supplementary Analysis from JCOG0502临床期I食管癌行二野或三野淋巴结清扫术食管切除术后的术后复发模式：JCOG0502研究的补充分析
errANNALS OF SURGICAL ONCOLOGY
IF3.5
err2025-05-09
err0
PREAI
errBamba, Takeo; Kato, Ken; Daiko, Hiroyuki; Ito, Yoshinori; Kajiwara, Takeshi; Fujita, Takeo; Miyata, Hiroshi; Machida, Ryunosuke; Sasaki, Keita; Takeuchi, Hiroya; Kitagawa, Yuko
err分享
err收藏
First-Line Tislelizumab Plus Chemotherapy for Esophageal Squamous Cell Carcinoma with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-306一线Tislelizumab联合化疗治疗程序性死亡配体1表达 ≥ 1% 的食管鳞状细胞癌: 原理306的回顾性分析
errADVANCES IN THERAPY
IF4
err2025-03-01
err0
errOAAI
errXu, Jianming; Kato, Ken; Hubner, Richard; Park, Sook Ryun; Kojima, Takashi; Ishihara, Ryu; Wyrwicz, Lucjan; Van Cutsem, Eric; Jimenez-Fonseca, Paula; Wu, Hongqian; Wang, Lei; Yan, Sebastian; Shi, Jingwen; Kadva, Alysha; Yoon, Harry H.
err分享
err收藏
First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305一线Tislelizumab联合化疗治疗程序性死亡配体1表达 ≥ 1% 的晚期胃癌: 原理305的回顾性分析
errADVANCES IN THERAPY
IF4
err2025-03-01
err0
errOAAI
errMoehler, Markus; Oh, Do-Youn; Kato, Ken; Arkenau, Tobias; Tabernero, Josep; Lee, Keun-Wook; Rha, Sun Young; Hirano, Hidekazu; Spigel, David; Yamaguchi, Kensei; Wyrwicz, Lucjan; Disel, Umut; Pazo-Cid, Roberto A.; Fornaro, Lorenzo; Xu, Yaling; Sheng, Tao; Yang, Silu; Kadva, Alysha; Cruz-Correa, Marcia; Xu, Rui-Hua
err分享
err收藏
The Relationship Between the Percent Coefficient of Variation of Sensor Glucose Levels and the Risk of Severe Hypoglycemia or Non-Severe Hypoglycemia in Patients With Type 1 Diabetes: Post Hoc Analysis of the ISCHIA Study
errJOURNAL OF DIABETES SCIENCE AND TECHNOLOGY
IF3.7
err2025-02-17
err0
errOAAI
errMurata, Takashi; Matsuhisa, Munehide; Kuroda, Akio; Toyoda, Masao; Hirota, Yushi; Ogura, Masahito; Suzuki, Shota; Kato, Ken; Tone, Atsuhito; Matoba, Yuka; Meguro, Shu; Miura, Junnosuke; Nishimura, Kunihiro; Shimada, Akira; Hosoda, Kiminori; Sakane, Naoki; ISCHIA Study Grp
err分享
err收藏
Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment including fluoropyrimidine, platinum, and anti-PD-1/PD-L1 antibody (PADDLE)nab-紫杉醇联合雷莫芦单抗联合nivolumab治疗一线治疗进展后不可切除的晚期或复发性胃癌的II期试验，包括氟嘧啶，铂和anti-PD-1/PD-L1抗体 (PADDLE)
errBMC CANCER
IF3.4
err2025-02-04
err0
errOAAI
errHirano, Hidekazu; Takahashi, Naoki; Amanuma, Yusuke; Suzuki, Nobumi; Takahari, Daisuke; Kawakami, Takeshi; Kudo-Saito, Chie; Nagashima, Kengo; Boku, Narikazu; Kato, Ken; Shoji, Hirokazu
err分享
err收藏
Exploring novel therapeutic targets in small bowel adenocarcinoma: insights from claudin 18.2, nectin-4, and HER3 expression analysis探索小肠腺癌的新治疗靶点: 来自claudin 18.2，nectin-4和HER3表达分析的见解
errESMO OPEN
IF8.3
err2025-01-01
err0
errOAAI
errFujii, H.; Shoji, H.; Hirano, H.; Hirose, T.; Okita, N.; Takashima, A.; Kato, K.
err分享
err收藏

研究方向

暂时未获取到该数据
合作学者
合作期刊
E
Eric Van Cutsem
H 指数: 174 · 论文数: 1.8K
D
David Cunningham
H 指数: 153 · 论文数: 2.1K
J
Jaffer A. Ajani
H 指数: 152 · 论文数: 1.7K
J
Josep Tabernero
H 指数: 146 · 论文数: 2.7K
I
Iichiro Shimomura
H 指数: 114 · 论文数: 878
查看更多